TCM
ALPN icon

TCG Crossover Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

TCG Crossover Management’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-253,069
Closed -$2.6M – 28
2023
Q2 		$2.6M Hold
253,069
– – 0.43% 22
2023
Q1 		$1.95M Hold
253,069
– – 0.38% 22
2022
Q4 		$1.86M Sell
253,069
-1,500
-0.6% -$9.59K 0.33% 20
2022
Q3 		$1.83M Sell
254,569
-323,691
-56% -$2.67M 0.55% 20
2022
Q2 		$4.92M Sell
578,260
-455,962
-44% -$3.93M 2.09% 16
2022
Q1 		$9.28M Sell
1,034,222
-135,990
-12% -$1.18M 3.72% 11
2021
Q4 		$16.2M Buy
+1,170,212
New +$14.5M 7.59% 5

Other funds holding ALPN

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCG Crossover Management's ALPN Position: Q3 2023 in Review

TCG Crossover Management sold out of Alpine Immune Sciences Inc (ALPN) in Q3 2023, closing a stake of 253,069 shares — an estimated $2.6M sold.

TCG Crossover Management first reported a position in ALPN in Q4 2021 and held it in 7 quarters. The position peaked at $16.2M in Q4 2021. 88 funds tracked by Wall St. Rank hold ALPN as of Q3 2023.

  • TCG Crossover Management reported no remaining Alpine Immune Sciences Inc position as of Q3 2023 after selling out during the quarter.
  • TCG Crossover Management sold 253,069 Alpine Immune Sciences Inc shares in Q3 2023, an estimated $2.6M.
  • TCG Crossover Management first reported a position in Alpine Immune Sciences Inc in Q4 2021 and held it in 7 quarters.
  • TCG Crossover Management's Alpine Immune Sciences Inc position peaked at $16.2M in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q3 2023.

Based on TCG Crossover Management's 13F filing for Q3 2023, filed 14 Nov 2023.